Aprea Therapeutics Appoints Eugene Kennedy, MD, as Chief Medical Advisor to Advance WEE1 Inhibitor Program

Wednesday, Feb 4, 2026 8:32 am ET1min read
APRE--

Aprea Therapeutics has appointed Eugene Kennedy, MD, as Chief Medical Advisor. Kennedy is a seasoned physician scientist and biopharmaceutical executive with 20 years of experience in oncology clinical development, regulatory strategy, and senior corporate leadership. He will strengthen the Company's clinical leadership as it advances its WEE1-focused DNA damage response program and build on its recent early clinical proof-of-concept. Kennedy has a track record of leading complex oncology programs and supporting data-driven decisions.

Aprea Therapeutics Appoints Eugene Kennedy, MD, as Chief Medical Advisor to Advance WEE1 Inhibitor Program

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet